HC Wainwright & Co. Maintains Buy on TriSalus Life Sciences, Lowers Price Target to $10
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and lowers the price target from $12 to $10.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and lowers the price target from $12 to $10.